Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
- PMID: 10618400
- PMCID: PMC26645
- DOI: 10.1073/pnas.97.1.228
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
Abstract
Translocations involving c-myc and an Ig locus have been reported rarely in human multiple myeloma (MM). Using specific fluorescence in situ hybridization probes, we show complex karyotypic abnormalities of the c-myc or L-myc locus in 19 of 20 MM cell lines and approximately 50% of advanced primary MM tumors. These abnormalities include unusual and complex translocations and insertions that often juxtapose myc with an IgH or IgL locus. For two advanced primary MM tumors, some tumor cells contain a karyotypic abnormality of the c-myc locus, whereas other tumor cells do not, indicating that this karyotypic abnormality of c-myc occurs as a late event. All informative MM cell lines show monoallelic expression of c-myc. For Burkitt's lymphoma and mouse plasmacytoma tumors, balanced translocation that juxtaposes c-myc with one of the Ig loci is an early, invariant event that is mediated by B cell-specific DNA modification mechanisms. By contrast, for MM, dysregulation of c-myc apparently is caused principally by complex genomic rearrangements that occur during late stages of MM progression and do not involve B cell-specific DNA modification mechanisms.
Figures




Similar articles
-
Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.Genes Chromosomes Cancer. 2008 Jul;47(7):573-90. doi: 10.1002/gcc.20563. Genes Chromosomes Cancer. 2008. PMID: 18381641 Free PMC article.
-
Characterization of MYC translocations in multiple myeloma cell lines.J Natl Cancer Inst Monogr. 2008;(39):25-31. doi: 10.1093/jncimonographs/lgn011. J Natl Cancer Inst Monogr. 2008. PMID: 18647998 Free PMC article.
-
Dysregulation of c-myc in multiple myeloma.Curr Top Microbiol Immunol. 1997;224:277-82. doi: 10.1007/978-3-642-60801-8_29. Curr Top Microbiol Immunol. 1997. PMID: 9308252
-
Distinguishing primary and secondary translocations in multiple myeloma.DNA Repair (Amst). 2006 Sep 8;5(9-10):1225-33. doi: 10.1016/j.dnarep.2006.05.012. Epub 2006 Jul 10. DNA Repair (Amst). 2006. PMID: 16829212 Review.
-
Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma.Ann Oncol. 2000;11 Suppl 1:131-5. Ann Oncol. 2000. PMID: 10707795 Review.
Cited by
-
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.Mol Cancer Ther. 2012 Nov;11(11):2321-30. doi: 10.1158/1535-7163.MCT-12-0578. Epub 2012 Sep 10. Mol Cancer Ther. 2012. PMID: 22964485 Free PMC article.
-
UHRF1-KAT7-mediated regulation of TUSC3 expression via histone methylation/acetylation is critical for the proliferation of colon cancer cells.Oncogene. 2020 Jan;39(5):1018-1030. doi: 10.1038/s41388-019-1032-y. Epub 2019 Oct 3. Oncogene. 2020. PMID: 31582837
-
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.Leukemia. 2018 Oct;32(10):2224-2239. doi: 10.1038/s41375-018-0044-x. Epub 2018 Mar 27. Leukemia. 2018. PMID: 29581547 Free PMC article.
-
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.Blood. 2014 Sep 18;124(12):1915-25. doi: 10.1182/blood-2014-03-559385. Blood. 2014. PMID: 25122609 Free PMC article. Clinical Trial.
-
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.J Exp Med. 2007 Mar 19;204(3):633-43. doi: 10.1084/jem.20062041. Epub 2007 Mar 12. J Exp Med. 2007. PMID: 17353367 Free PMC article.
References
-
- Wiener F, Potter M. In: The Causes And Consequences Of Chromosomal Aberrations. Kirsch I R, editor. New York: CRC; 1993. pp. 91–124.
-
- Dalla-Favera R. In: The Causes And Consequences Of Chromosomal Aberrations. Kirsch I R, editor. New York: CRC; 1993. pp. 313–332.
-
- Korsmeyer S J. Annu Rev Immunol. 1992;10:785–807. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical